Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | KLK7 | P49862 | 2/20 | 0.34 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4188969 | 1.00 | SCN9A (0.37) | SCN9AGPR119KLK7KLK5GRM5 | |
| SCHEMBL4188966 | 1.00 | SCN9A (0.37) | SCN9AGPR119KLK7KLK5GRM5 | |
| SCHEMBL4180191 | 0.87 | SCN9A (0.33) | SCN9APOLBALDH1A1GAATSHR | |
| SCHEMBL4180187 | 0.87 | SCN9A (0.33) | SCN9APOLBALDH1A1GAATSHR | |
| SCHEMBL4180200 | 0.87 | SCN9A (0.33) | SCN9APOLBALDH1A1GAATSHR | |
| SCHEMBL2447629 | 0.84 | GRM5 (0.37) | SCN9AGPR119KLK7KLK5GRM5 | |
| SCHEMBL245192 | 0.84 | GRM5 (0.37) | SCN9AGPR119KLK7KLK5GRM5 | |
| SCHEMBL7772596 | 0.84 | ELANE (0.46) | GPR119KLK7KLK5 | |
| SCHEMBL4180233 | 0.80 | GPR119 (0.36) | GPR119KLK7KLK5POLB | |
| SCHEMBL4180242 | 0.80 | GPR119 (0.36) | GPR119KLK7KLK5POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | SCN9A 486/4885GPR119 1888/4885KLK7 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.